Giroctocogene Fitelparvovec
Gene therapyexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jun 2, 2017 (NCT03061201)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Coagulation factor VIIIEXOGENOUS GENE
Coagulation factor VIII exogenous gene
Gene therapy, factor VIII replacement
- Coagulation factor VIIISupplementation
F8 supplementation
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4298194 ↗
Also known as
- sb-525
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03061201 | Phase 1/Phase 2 (Phase 2) | Jun 2, 2017 | Sangamo BioSciences |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Sangamo BioSciences | For profit | 1 | 1 | 1 | 2017 |
1 organizations
Page 1 / 1